Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Next Previous
Trial Profile

Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palopegteriparatide (Primary)
  • Indications Hypoparathyroidism
  • Focus Expanded access; Therapeutic Use
  • Sponsors Ascendis Pharma Bone Diseases

Most Recent Events

  • 27 Apr 2023 According to an Ascendis Pharma media release, 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years and this USA Expanded Access Program continues to enroll new patients.
  • 04 Jan 2023 According to an Ascendis Pharma media release, the online portal is now open for physicians wanting to request access to TransCon PTH (palopegteriparatide), through this U.S. Expanded Access Program (EAP). Requests for access must be made by the patients treating physician through the program administrator, Clinigen Healthcare LTD, at Palopegteriparatide - Clinigen (clinigengroup.com). or by searching palopegteriparatide on the Clinigen Direct homepage: https://www.clinigengroup.com/direct/en/.
  • 07 Dec 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top